Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies

Journal of Pharmacological and Toxicological Methods

Volumn 75, Issue , 2015, Pages 101-110

  Benjamin, Amanda ^a   Gallacher, David J ^b   Greiter Wilke, Andrea ^c   Guillon, Jean Michel ^d   Kasai, Cheiko ^e   Ledieu, David ^f   Levesque, Paul ^g   Prelle, Katja ^h   Ratcliffe, Sian ⁱ   Sannajust, Frederick ^j   Valentin, Jean Pierre ^a,k  

^a ASTRAZENECA   (United Kingdom)

^b Mechanistic Pharmacology Janssen   (Belgium)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d SANOFI   (France)

^e ASTELLAS PHARMA INC   (Japan)

^f NOVARTIS PHARMA AG   (Switzerland)

^g BRISTOL MYERS SQUIBB   (United States)

^h Safety Pharmacology Bayer HealthCare   (Germany)

ⁱ PFIZER INC   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k Non Clinical Development   (Belgium)

more..

Author keywords

DIKI biomarkers; ICH S7A; Kidney; Safety pharmacology; Strategy

Indexed keywords

BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ARTICLE; DECISION MAKING; DISEASE MARKER; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TOXICITY; HEALTH SURVEY; MATHEMATICAL COMPUTING; MEASUREMENT; NEPHROTOXICITY; PHARMACOLOGY; TOXICITY TESTING; URINALYSIS; VALIDATION STUDY; ADVERSE DRUG REACTION; ANIMAL; CHEMICALLY INDUCED; DRUG DESIGN; HUMAN; KIDNEY DISEASE; METABOLISM; PRECLINICAL STUDY; PROCEDURES; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ANIMALS; BIOMARKERS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; KIDNEY DISEASES; SURVEYS AND QUESTIONNAIRES; TOXICITY TESTS;

EID: 84942553798     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2015.01.004     Document Type: Article

References (38)

1. Anon ICHS7A: Safety pharmacology studies for human pharmaceuticals London. CPMP/ICH/539/00. (Last accessed 11/12/2013). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf.
2. Anon ICH M3 (R2): Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals CPMP/ICH/286/95. (Last accessed 28/04/2014). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf.
3. Anon OECD guidance document 116 on the conduct and design of chronic toxicity and carcinogenicity studies, supporting test guidelines 451, 452 and 453 2nd edition (Last accessed 11/12/2013). http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=ENV/JM/MONO(2011)47&doclanguage=en.
4. Bonventre J.V., Vaidya V.S., Schmouder R., Feig P., Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nature Biotechnology 2010, 28:436-440.
5. Chen Y., Brott D., Luo W., Gangl E., Kamendi H., Barthlow H., et al. Assessment of cisplatin-induced kidney injury using an integrated rodent platform. Toxicology and Applied Pharmacology 2013, 268:352-361.
6. Choudhury D., Ahmed Z. Drug-associated renal dysfunction and injury. Nature Clinical Practice Nephrology 2006, 2:80-91.
7. Dieterle F., Perentes E., Cordier A., Roth D.R., Verdes P., Grenet O., et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nature Biotechnology 2010, 28:463-469.
8. Dieterle F., Sistare F., Goodsaid F., Papaluca M., Ozer J.S., Webb C.P., et al. Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nature Biotechnology 2010, 28:455-462.
9. Eisner C., Faulhaber-Walter R., Want Y., Leelahavanichkul A., Yuen P.S.T., Mizel D., et al. Major contribution of tubular secretion to creatinine clearance in mice. Kidney International 2010, 77:519-526.
10. Ewart L., Gallacher D.J., Gintant G., Guillon J.M., Leishman D., Levesque P., et al. How do the top 12 pharmaceutical companies operate SP?. Journal of Pharmacological and Toxicological Methods 2012, 66(2):66-70.
11. Ferguson M.A., Vaidya V.S., Bonventre J.V. Biomarkers of nephrotoxic acute kidney injury. Toxicology 2008, 245:182-193.
12. Friedrichs G.S., Patmore L., Bass A. Non-clinical evaluation of ventricular repolarization (ICH S7B): Results of an interim survey of international pharmaceutical companies. Journal of Pharmacological and Toxicological Methods 2005, 52:6-11.
13. Fuchs T.C., Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity - An overview for applied toxicology. The AAPS Journal 2011, 13:615-631.
14. Gabel R.A., Ranaei R.A., Kivlighn S.D. A new method of measuring renal function in conscious rats without the use of radioisotopes. Journal of Pharmacological and Toxicological Methods 1996, 36:189-197.
15. Garner D., Laks M.M. Technique for the performance of repeatable renal clearances in the conscious male dog. Nephron 1976, 16:143-147.
16. Garrett M.D., Workman P. Discovering novel chemotherapy drugs for the third millennium. European Journal of Cancer 1999, 35:2010-2030.
17. Guha M., Heier A., Price S., Bielenstein M., Caccase R.G., Heathcote D.I., et al. Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor. Toxicological Sciences 2011, 120:269-283.
18. Katayama R., Yamaguchi N., Yamashita T., Watanabe S., Satoh H., Yamagishi N.And, et al. Calculation of glomerular filtration rate in conscious rats by the use of a bolus injection of iodixanol and a single blood sample. Journal of Pharmacological and Toxicological Methods 2010, 61:59-64.
19. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews Drug Discovery 2004, 3:711-716.
20. Lesco L.K., Atkinson A.J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annual Review of Pharmacology and Toxicology 2001, 41:347-366.
21. Liano F., Pascual J. Epidemiology of acute renal failure: A prospective, multicenter, community based study. Madrid Acute Renal Failure Study Group. Kidney International 1996, 50:811-818.
22. Lindgren S., Bass A.S., Briscoe R., Bruse K., Friedrichs G.S., Kallman M.J., et al. Benchmarking safety pharmacology regulatory packages and best practice. Journal of Pharmacological and Toxicological Methods 2008, 58:99-109.
23. Matheis K., Laurie D., Andriamandroso C., Arber N., Badimon L., Benain X., et al. A generic operational strategy to qualify translational safety biomarkers. Drug Discovery Today 2011, 16:600-608.
24. McIlroy D.R., Wagener G.And, Lee H.T. Biomarkers of acute kidney injury: An evolving domain. Anesthesiology 2010, 112:998-1004.
25. Mehta R.L., Pascual M.T., Soroko S., Savage B.R., Himmelfarb J., Ikizler T.A., et al. Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney International 2004, 66:1613-1621.
26. Ozer J.S., Dieterle F., Troth S., Perentes E., Cordier A., Verdes P., et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nature Biotechnology 2010, 28:486-494.
27. Qi Z., Whitt I., Mehta A., Jin J., Zhae M., Harris R.C., et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. American Journal of Physiology - Renal Physiology 2004, 286:F590-F596.
28. Redfern W.S., Ewart L., Hammond T.G., Bialecki R., Kinter L., Lindgren S., et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 2010, 114(S1):1081.
29. Redfern W.S., Ewart L., Lainee P., Robinson S., Valentin J.P. Functional assessments in repeat-dose toxicity studies: The art of the possible. Toxicology Research 2013, 2:209-234.
30. Rouse R., Zhang J., Stewart S.R., Rosenzweig B.A., Espandiari P., Sadrieh N.K. Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats. Kidney International 2011, 79:1186-1197.
31. Sasaki D., Yamada A., Umeno H., Kurihara H., Nakatsuji S., Fujihira S., et al. Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury. Biomarkers 2011, 16(7):553-566.
32. Schock-Kusch D., Xie Q., Shulhevich Y., Hesser J., Stsepankou D., Sadick M., et al. Transcutaneous assessment of renal function in conscious rats with a device for measuring FITC-sinistrin disappearance curves. Kidney International 2011, 79:1254-1258.
33. Schreiber A., Shulhevich Y., Geraci S., Hesser J., Stsepankou D., Neudecker S., et al. Transcutaneous measurement of renal function in conscious mice. American Journal of Physiology - Renal Physiology 2012, 303:F783-F788.
34. Sieber M., Hoffmann D., Adler M., Vaidya V.S., Clement M., Bonventre J.V., et al. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicological Sciences 2009, 109(2):336-349.
35. Pharmaprojects®, 2012 Citeline Source of data for size of R&D portfolio (accessed in October 2013), (Last accessed 04/12/2013). http://www.citeline.com/resource-center/whitepapers/.
36. Stockham S.L., Scott M.A. Urinary system. Fundamentals of Veterinary Clinical Pathology 2008, Wiley-Blackwell, (Chapter 8). 2nd ed.
37. Valentin J.P., Hammond T.G. Safety pharmacology: Past, present and future. The Process of New Drug Discovery and Development 2006, 243-290. Informa Healthcare USA Inc., New York. C.G. Smith, J. O'Donnell (Eds.).
38. Yu Y., Jin H., Holder D., Ozer J.S., Villarreal S. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nature Biotechnology 2010, 28:470-477.